Sprout Group
VC Fund
New York, United States
Sprout Group is a VC fund in New York focused on Health Care and Biotechnology. Sprout Group is one of the oldest and largest institutional venture capital firms focused on emerging companies. Since its founding in 1969, Sprout Group has financed more than 350 companies and has raised nearly $3.0 billion in committed capital from leading institutional investors and individuals. In November 2000, Sprout Group closed Sprout IX,a fund totaling $1.1 billion.
- Total investments:
- 109
- Last investment:
- Lead investor:
- 28%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sprout Group invests in
Stages Sprout Group invests in
Countries Sprout Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series B
- $8M–$70M
- Series C
- $8.5M–$80M
Investment Focus
Industry
- Health Care 22 (20%)
- Biotechnology 15 (14%)
- Medical 14 (13%)
- Software 12 (11%)
- Internet 10 (9%)
Stage
- Series B 26 (24%)
- Series C 20 (18%)
- Funding Round 18 (17%)
- Series A 13 (12%)
- Series D 13 (12%)
Country
- United States 61 (56%)
- Canada 2 (2%)
- India 1 (1%)
- United Arab Emirates 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Craig Parker
Director
|
Director | Total investments: 0 | Find email | |
|
Craig Parker
Director
|
Director | Total investments: 1 | Find email | |
Janet Hickey
Co-Managing Partner
|
Co-Managing Partner | Total investments: 2 | Find email | |
|
Steve Rattner
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CallFixie
|
CallFixie is a new, FREE online service that connects tradies and customers Australia wide. Unlike Their competitors, They have no sign up or ongoing subscription fees.As a customer, it is FREE to post your job and, as a Fixie, it is FREE to post unlimited quotes. Their easy-to-use website and mobile apps take the hassle out of finding aqualified tradie (or, as They like to call them, “Fixies”) to get your job SORTED.CallFixie gives you access to thousands of Fixies across Australia, covering all trades and services. So, no matter where you are or how big or small your job is, CallFixie will get it SORTED. | $2M / Seed / Mar 31, 2016 | |
Relypsa
|
Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa isdedicated to discover additional product candidates through use of its proprietary polymer platform. | $80M / Series C / Aug 14, 2012 | |
|
Relypsa
|
Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa isdedicated to discover additional product candidates through use of its proprietary polymer platform. | $62.4M / Private Equity / Jul 01, 2012 | |
|
Relypsa
|
Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa isdedicated to discover additional product candidates through use of its proprietary polymer platform. | $70.1M / Series B / Aug 08, 2011 | |
CyOptics
|
CyOptics, Inc. designs, develops, and markets Indium Phosphide (InP) optical chips and components for integration into access, metro, and long-haul communications systems. Its products include planar lightwave circuits (PLCs) for optical networks in telecommunications and defense applications. The company's products also include opticalcomponents, including transmitters, receivers, and modulators for transmission; and optical source and laser detector chips as technology enablers for transmit optical sub-assembly/receive optical sub-assembly, component, and module manufacturers. In addition, it provides contract design, foundry, and packaging services; and design and manufacturing services, such as radio frequency and optical design, wafer/chip fabrication, and automated assembly and test for telecom and non-telecom applications. The company's customers include system original equipment manufacturers and sub-system manufacturers in the communications market. CyOptics, Inc. was founded in 1999 and is based in Breinigsville, Pennsylvania. The company has InP design and fabrication operations in Lehigh Valley, Pennsylvania; silicon PLC fab operations in South Plainfield, New Jersey; and planar automated packaging and testing operations in Matamoros, Mexico. | $50M / Private Equity / Jan 26, 2011 | |
|
Relypsa
|
Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa isdedicated to discover additional product candidates through use of its proprietary polymer platform. | $70M / Series B / Sep 13, 2010 | |
Aureon Laboratories
|
Aureon Laboratories is a life sciences company dedicated to enabling the advancement of predictive and personalized cancer treatment. Aureon provides objective, actionable information allowing patients and physicians to make more-informed treatment decisions through its prostate diagnostic tools. | $7M / Series D / Apr 14, 2010 | |
TradeBeam
|
TradeBeam provided trade management software and services company streamlining global trading processes for enterprises and their partners. | $7M / Sep 21, 2009 | |
Calix
|
Calix cloud and software platforms enable service providers of all types and sizes to innovate and transform. Our customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates morevalue for their businesses and communities. This is the Calix mission; to enable communications service providers of all sizes to simplify, excite and grow. | $50M / Aug 31, 2009 | |
CareDx
|
CareDx is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information. XDx has one marketed product, AlloMap Molecular Expression Testing, and other products underdevelopment. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored. | $14.4M / Series G / Aug 05, 2009 | |
| See all 109 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Sprout Group invest in?
Sprout Group invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 109 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sprout Group's check size?
Sprout Group typically joins rounds of $8M–$70M at Series B and $8.5M–$80M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sprout Group participates in.
How do I contact Sprout Group?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sprout Group?
The team at Sprout Group includes Craig Parker (Director), Craig Parker (Director) and Janet Hickey (Co-Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
